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Genetic associations at a genome-wide significance level in PSC1 have 
only previously been detected within the human leukocyte antigen 
(HLA) complex on chromosome 6p21 (ref. 2). In the majority of HLA-
associated diseases, additional susceptibility genes have been identi-
fied at other chromosomal loci3. The heritability in PSC is estimated 
to be in the same range as most of these other HLA-associated condi-
tions (with a relative sibling risk of approximately 10)4, suggesting a 
similar genetic architecture. To identify non-HLA susceptibility loci 
for PSC, we analyzed 332 Scandinavian PSC cases and 383 German 
PSC cases, along with 262 Scandinavian controls and 2,700 German 
controls genotyped with the Affymetrix Genome-Wide Human SNP 
Array 6.0 (Affymetrix). Two hundred sixty of the cases and 262 of 
the controls were included in a previous genome-wide assessment 
of 375,487 SNPs2. The power to detect association at a genome-wide 
significance level with a log-additive model in the discovery panel 
was 80% for a SNP with a frequency of 40% in the controls and an 
odds ratio of 1.42 (Supplementary Fig. 1). For a detailed descrip-
tion of the study populations and the experimental protocols, see the 
Supplementary Methods.
We applied extensive quality control measures5 and excluded 
 samples with a low genotyping success rate (<95%), heterozygo-
sity outliers and samples with evidence for cryptic relatedness. We 
assessed study population heterogeneity by means of a principal com-
ponents analysis6 (Supplementary Fig. 1), and we removed ethnic 
outliers before proceeding with further analyses. We also excluded 
SNPs with a minor allele frequency <1%, a genotyping success 
rate <95% or a deviation of the genotype distribution from Hardy-
Weinberg equilibrium in the controls (P < 10−4). To increase the 
genomic coverage of the dataset, we imputed missing genotypes and 
SNPs using the phased European CEU HapMap data release 22 refer-
ence dataset. We subjected all imputed markers to the same quality 
criteria described above and added the requirement of good impu-
tation quality, leaving a total of 2,466,182 SNPs for association ana-
lysis. We used a logistic regression procedure to test both genotyped 
and imputed SNPs for association. We used allele dosages from the 
 imputation to account for uncertainty in the imputation procedure, 
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and we included the first six principal components as covariates to 
adjust for population structure (Supplementary Fig. 1).
In line with our previous study2, we detected the strongest associa-
tions with PSC at SNPs in the HLA complex at chromosome 6p21, 
peaking at rs3134792 in HLA-B (P = 6.8 × 10−49) (Supplementary 
Fig. 2). Carriers of the associated G allele at rs3134792 were HLA-B*08 
carriers in 99% of the cases and were HLA-DRB1*03 carriers in 90% of 
the cases (Supplementary Methods). Inclusion of rs3134792 as a cov-
ariate in our model showed a complex residual association signal in 
the vicinity of the class II region (lowest P = 7.6 × 10−17 for rs9272723), 
suggesting the presence of multiple causative loci within the region 
(Supplementary Fig. 2). In ulcerative colitis, the association signal 
in the HLA complex is less extensive (Supplementary Fig. 3), with 
associated SNPs predominantly being observed near the HLA class II 
genes, and dedicated studies will be needed to differentiate between 
disease-specific and shared risk variants for PSC and ulcerative colitis 
in this region. In addition to SNPs in the HLA complex, multiple 
SNPs in strong linkage disequilibrium (LD) at chromosome 3p21 were 
also associated at a genome-wide significance level. The 3p21 signal 
stretches over a 0.34-Mb interval and peaks at rs3197999 in MST1, 
the macrophage stimulating 1 gene (P = 1.4 × 10−9) (Fig. 1a). Three 
hundred seventy-nine non-HLA SNPs (that is, excluding markers in 
the region between 25 Mb and 35 Mb on chromosome 6) with P < 10−4 
were subsequently evaluated for replication genotyping. To exclude 
technical artifacts, we visually inspected raw intensity cluster plots 
for the genotyped SNPs. By grouping correlated SNPs based on LD 
(Supplementary Methods), we defined the top 23 associated regions 
for follow up. We performed replication genotyping using Sequenom 
mass spectrometry–based technology and a total of 1,025 PSC cases 
along with 2,174 controls from Scandinavia, Central Europe and the 
United States (see Supplementary Table 1 for a complete listing and 
for allele frequencies).
In the replication analysis, we detected the most prominent asso-
ciation for the non-synonymous (p.Arg689Cys) SNP rs3197999 at 
MST1 (Table 1). This PSC-associated amino acid change has pre-
viously been proposed to influence MST1 receptor interaction, as 
well as the risk for ulcerative colitis and Crohn’s disease7. The present 
finding suggests that the MST1 locus represents an important over-
lapping susceptibility locus for PSC and inflammatory bowel disease 
and that the influence from the disease-associated variant on biliary 
and intestinal inflammation needs to be further studied. The fact that 
the MST1 protein is expressed at high levels in gallbladder epithelium 














































































































figure 1 Association results at the MST1 and 
BCL2L11 loci. (a,c) The association results from 
the genotyped and imputed markers at the MST1 
and BCL2L11 loci are shown as the –log10 of the 
P values plotted against the genomic position 
(NCBI build 36). The MST1 and BCL2L11 
SNPs with robust evidence for replication 
are highlighted with green circles. (b,d) The 
recombination rates (gray lines) derived from 
the HapMap project, along with the association 
results based on an imputed dataset using 
reference data from the 1000 Genomes Project. 
None of the imputed 1000 Genomes Project 
SNPs in the region from 111,745,000 bp  
to 111,929,500 bp on chromosome 2 passed 
imputation quality thresholds (supplementary 
methods). The MST1 and BCL2L11 associations 
(represented by the SNPs given in table 1) were 
independent of the HLA association in a logistic 
regression analysis with inclusion of rs3134792 
(the most strongly associated HLA SNP) as a 
covariate and in a stratified analysis according to 
rs3134792 risk allele carriership (supplementary 
table 2). Association results at the MST1 and 
BCL2L11 loci in ulcerative colitis compared to 
PSC are shown in supplementary figure 3.
table 1 snPs with significant association results in the replication cohort
Locus SNP Chr. Position Alleles
Genome-wide analysis Replication analysis
Combined P























MST1 rs3197999 3 49,696,536 A/G 0.36/0.32 0.40/0.28 1.4 × 10–9 1.51  
(1.32–1.72)
0.35/0.31 0.33/0.25 0.38/0.30 1.5 × 10–8 1.39  
(1.24–1.56)
1.1 × 10–16
BCL2L11 rs6720394 2 111,705,843 G/T 0.17/0.13 0.15/0.11 5.2 × 10–6 1.60  
(1.31–1.96)
0.14/0.12 0.13/0.11 0.16/0.10 0.0016 1.29  
(1.10–1.51)
4.1 × 10–8
Association results for the genome-wide analysis and the replication analysis for the two SNPs with replication results robust to correction for multiple testing using Bonferroni’s method.  
We performed association testing with logistic regression including correction for population structure in the genome-wide discovery analysis, and the Cochran-Mantel-Haenszel test was  
used for the replication analysis. Allele frequencies are given for each of the five study panels separately. Positions refer to NCBI’s build 36. CMH, Cochran-Mantel-Haenszel; OR, odds ratio;  
Chr., chromosome.
aOdds ratios and P values derived from logistic regressions of allele dosages including the first six principal components from the principal components analysis as covariates. bCochran-Mantel-Haenszel test; 
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(antibody ID HPA024036; Human Protein Atlas) further supports 
this notion. In addition, the strong LD present in this region (Fig. 1b) 
means that further genetic characterization is necessary to exclude the 
presence of several susceptibility variants at the 3p21 locus.
The replicated association signal at chromosome 2q13 (Table 1) was 
supported by multiple SNPs (Fig. 1c,d) encompassing the BCL2L11 
(encoding the BCL2-like 11 protein) locus and extending into a dupli-
cated region with a transcript of unknown function (LOC541471). 
BCL2L11 encodes the Bcl-2 interacting protein (Bim), which is 
 crucial for maintaining immunological tolerance through induction 
of apoptosis of autoreactive T cells, as well as the deletion of activated 
T cells after an immune response8. The neighboring putative gene, 
LOC541471, is very unlikely to give rise to protein-coding transcripts, 
as these transcripts contain only short open reading frames that do 
not match any known protein homolog (Supplementary Fig. 4). 
Although it can not be completely ruled out that the LOC541471 
transcripts function as non–protein-coding RNA, we conclude that 
the lead SNP, rs6720394, is more likely to represent genetic variation 
that affects BCL2L11 rather than LOC541471. To gain potential 
insight into a role of Bim in biliary physiology, we assessed hepatic 
hematoxylin and eosin stainings of 8-week-old Bcl2l11−/− mice and 
matched wildtype controls (Supplementary Methods). Although 
both genotypes presented with histologically normal livers, it was 
remarkable that in four out of four Bcl2l11−/− livers, mononuclear 
cells were present surrounding several intrahepatic bile ducts, whereas 
none of the portal fields in four wildtype livers showed similar subtle 
alterations (P = 0.029) (Supplementary Fig. 5). Further mechanistic 
studies aimed at characterizing Bim’s functional effects on liver and 
biliary physiology appear warranted.
At the IL2RA (encoding interleukin 2 receptor alpha) locus, sev-
eral SNPs showed highly significant association in the genome-wide 
analysis (lowest P = 2.4 × 10−7, for rs10905718) (Supplementary 
Fig. 2). This locus is of particular interest in PSC because Il2ra−/− 
mice spontaneously develop both intestinal and biliary inflamma-
tion9. Notably, although the Il2ra−/− model has been proposed to 
mimic pathogenesis in another disease of the bile ducts (primary 
biliary cirrhosis), no association at IL2RA was reported in a genome-
wide analysis of this condition10. The SNPs at IL2RA selected for 
 replication based on the genome-wide analysis demonstrated non-
uniform effect sizes in the replication analysis (Breslow-Day test, P < 
0.05) and did not achieve nominal significance when analyzed with a 
random effects model (Supplementary Table 1). The lack of formal 
replication at the IL2RA locus could be due to population differ-
ences, which we could not correct for because genome-wide data were 
not available for the replication panels. For IL2RA SNPs previously 
shown to influence risk of multiple sclerosis and type 1 diabetes3, we 
observed significant associations in the genome-wide analysis (P = 
8.7 × 10−4 for rs2104286 and P = 0.0025 for rs12251307, respectively), 
as well as similar trends in the replication analysis (Cochran-Mantel-
Haenszel (CMH), P = 0.064 for rs2104286 and CMH, P = 0.033 for 
rs12251307; Breslow-Day, P = 0.30 and P = 0.39, respectively). The 
heterogeneous association signal at this locus makes it impossible 
to conclude genetically regarding an involvement of IL2RA in PSC 
pathogenesis, yet the combined evidence from the statistical associa-
tion analysis and the results from the Il2ra−/− mouse makes such an 
involvement possible.
In conclusion, to our knowledge, we are able to provide the first 
evidence at genome-wide significance for involvement of a non-
HLA gene in PSC susceptibility. Furthermore, we are able to provide 
 suggestive evidence for at least two additional loci involved in T cell 
activation and immunological tolerance, supporting the possibility 
raised by the strong HLA associations that PSC pathogenesis has an 
autoreactive component.
URLs. HapMap, http://www.hapmap.org/; Human Protein Atlas, 
http://www.proteinatlas.org/; 1000 Genomes Project, http://www. 
1000genomes.org/.
Note: Supplementary information is available on the Nature Genetics website.
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